Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors
Lung cancer is a malignant tumor with high incidence rate and mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common malignancy. The traditional treatment of NSCLC mainly depends on chemical drugs. In recent years, immunotherapy has become a hot spot in the treatment of NSCLC and...
Main Authors: | WANG Shuo, DENG Yuntian, PENG Huan, ZHANG Xiangfeng |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Office of Medical Journal of Peking Union Medical College Hospital
2023-03-01
|
Series: | Xiehe Yixue Zazhi |
Subjects: | |
Online Access: | https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2022-0151 |
Similar Items
-
Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer
by: Benlin HUANG, et al.
Published: (2019-04-01) -
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
by: Shengjie Tang, et al.
Published: (2022-01-01) -
Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer
by: Jiahui He, et al.
Published: (2023-03-01) -
Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
by: Lijun Peng, et al.
Published: (2022-09-01) -
Immune Checkpoint Inhibitors in Cancer Therapy
by: Yavar Shiravand, et al.
Published: (2022-04-01)